Moving averages are one of the core indicators in technical analysis. A Simple Moving Average (SMA) is simply the arithmetic average of stock price over a period. It is calculated by adding a selected range of prices, usually closing prices, and then dividing that figure by the number of time periods in that range.
The 50-Day SMA calculates the average price over 50 days. And the 20-Day SMA and 200-Day SMA calculates the average price over 20 days and 200 days separately.
As of today (2026-06-30), NeuroPace's 50-Day SMA is $16.38. It's 20-Day SMA is $15.88 and 200-Day SMA is $14.47.
NeuroPace (NAS:NPCE) 50-Day SMA Explanation
Simple Moving Average (SMA) is the arithmetic average of stock price over a period. The 20-Day SMA calculates the average price over 20 days. And the 50-Day SMA and 200-Day SMA calculates the average price over 50 days and 200 days separately. SMAs are often used to determine the price trend direction. A 200-Day SMA is usually a proxy for the long-term trend, while shorter periods indicate short-term trend.
SMA are commonly compared with stock price or different period SMAs to indicate a trading signal. Generally speaking, if the price goes above the SMA, or a short-term SMA crosses above a long-term SMA, an uptrend is expected, investors may want to go long or cover short. Conversely, if the price goes below the SMA, or the short-term SMA crosses below a long-term SMA, a downtrend is expected, investors may want to go short or exit long.
Two popular trading patterns that use SMA include the death cross and a golden cross. A death cross occurs when the 50-day SMA crosses below the 200-day SMA. This is considered a bearish signal, that further losses are in store. The golden cross is a bullish signal which occurs when a short-term SMA crosses above a long-term SMA.
NeuroPace 50-Day SMA Related Terms
NPCE vs CLPT, CTKB, CERS: 50-Day SMA Comparison
For the Medical Devices subindustry, NeuroPace's 50-Day SMA, along with its competitors' market caps and 50-Day SMA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NeuroPace 50-Day SMA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NeuroPace's 50-Day SMA distribution charts can be found below:
* The bar in red indicates where NeuroPace's 50-Day SMA falls into.
where:
Pn is the price of the stock at period n.
n is the total number of periods.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NeuroPace (NPCE) has a 50-Day SMA of $16.38 as of Jun. 30, 2026. Simple Moving Average (SMA) is the arithmetic average of stock price over a period. View historical data on NeuroPace and its competitors.
Is NeuroPace's 50-Day SMA too high?
NeuroPace's current 50-Day SMA is $16.38. Overall, NeuroPace has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NeuroPace's 50-Day SMA compare to CLPT and CTKB?
NeuroPace's 50-Day SMA of $16.38 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 50-Day SMA for a Medical Devices & Instruments company?
A good 50-Day SMA depends on the Medical Devices & Instruments industry context. However, 50-Day SMA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 50-Day SMA mean?
A high 50-Day SMA can signal that a stock is expensive relative to its fundamentals. Simple Moving Average (SMA) is the arithmetic average of stock price over a period. View historical data on NeuroPace and its competitors. NeuroPace's current 50-Day SMA is $16.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuroPace stock overvalued right now?
Based on GuruFocus' analysis, NeuroPace (NPCE) is currently considered Significantly Overvalued. The stock's GF Value™ is $11.41, compared to a current price of $15.90 — trading 39.4% above its estimated fair value. The current 50-Day SMA is $16.38. NeuroPace's overall GF Score™ is 65/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 50-Day SMA calculated?
50-Day SMA is calculated from a company's financial statements. For NeuroPace (NPCE), the current 50-Day SMA is $16.38 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NeuroPace (NPCE) Overvalued in 2026?
Based on GuruFocus' analysis, NeuroPace stock appears to be overvalued.
The current stock price of $15.90 is trading 39.4% above its estimated GF Value™ of $11.41.
GuruFocus considers NeuroPace to be Significantly Overvalued.
Key valuation signals for NPCE:
50-Day SMA: $16.38
GF Value™: $11.41 vs. price of $15.90 (39.4% above fair value)
No single metric tells the full story. See the NPCE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.
65GF Score
Get the complete analysis for NPCE
50-Day SMA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NPCE has been successfully added to your 